Composition:
Each Zerifax tablet contains 550mg of rifaximin
Description:
Zerifax tablets contain rifaximin, a non-aminoglycoside semi-synthetic, non-systemic antibiotic derived from rifamycin. Rifaximin is a structural analog of rifampin
Indications:
Travelers’ Diarrhea:
Zerifax 200mg is indicated for the treatment of patients (≥ 12 years of age) with travelers’ diarrhea caused by noninvasive strains of Escherichia coli.
Limitations of Use: Zerifax should not be used in patients with diarrhea complicated by fever or blood in the stool or diarrhea due to pathogens other than Escherichia Coli.
Irritable Bowel Syndrome with Diarrhea: Zerifax is indicated for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.
Hepatic Encephalopathy: Zerifax 550mg is indicated for reduction in risk of overt hepatic encephalopathy (HE) recurrence in patients 18 years of age.
Dosage:
Dosage for Travelers’ Diarrhea:
The recommended dose of Zerifax is one 200 mg tablet taken orally three times a day for 3 days. Zerifax can be administered orally, with or without food.
Dosage for Irritable Bowel Syndrome with Diarrhea: The recommended dose of Zerifax is one 550mg tablet taken orally three times a day for 14 days. Patients who experience a recurrence of symptoms can be retreated up to two times with the same dosage regimen.
Dosage for Hepatic Encephalopathy: The recommended dose of Zerifax is one 550 mg tablet taken orally two times a day, with or without food.